End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. Journal Of Clinical Oncology 2023, 41: 4729-4738. PMID: 37339389, PMCID: PMC10602547, DOI: 10.1200/jco.22.02180.Peer-Reviewed Original ResearchConceptsSystemic treatmentEnd of lifeWhite patientsBlack patientsOdds ratioLarge real-world populationPractice settingsTreatment ratesPatient-level factorsEmergency department useIntensive care unitReal-world populationDay of deathImmunotherapy eraSystemic therapyOncologic treatmentCare unitDeidentified databaseDepartment usePatient raceInsurance typeMetastatic cancerDownstream careMedicaid patientsHigher oddsThe impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM).
Adelson K, Canavan M, Sheth K, Scott J, Westvold S. The impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM). Journal Of Clinical Oncology 2023, 41: e18923-e18923. DOI: 10.1200/jco.2023.41.16_suppl.e18923.Peer-Reviewed Original ResearchSystemic anticancer therapyDay of deathOncology Care ModelEnd of lifeAcute care useSystemic therapyCT patientsCare useImpact of receiptMean episode costReceipt of chemotherapyReceipt of immunotherapyICU useED costsIO patientsPharmacy costsOncology practiceEpisode costsTreatment decisionsDownstream careCare modelAmbulatory settingPart BPatientsImmunotherapy